Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Real-time Quote. Real-time Tradegate - 08/25 10:03:35 pm
95.205 EUR   -1.79%
08/19 MERCK : EMD Serono Receives CEO Cancer Gold Standard ReAccreditation
08/16 MERCK : Millipore teams with TEAM Jaffrey
08/04DJMERCK KGAA : Lifts Profit Outlook as Sales Jump -- Update
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Merck : EMD Serono Receives CEO Cancer Gold Standard Re-Accreditation

share with twitter share with LinkedIn share with facebook
share via e-mail
08/25/2016 | 06:25pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that it has earned CEO Cancer Gold Standard™ re-accreditation for maintaining a strong commitment to the health of its employees and satisfying the latest, comprehensive requirements of this national workplace wellness accreditation program established by the CEO Roundtable on Cancer (see also Pharmaceutical Companies).


The CEO Roundtable on Cancer is a forum that brings together key cancer leaders from government, business, academic and non-profit sectors to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to the best available treatments and hasten the discovery of novel anti-cancer therapies. Founded by former President George H.W. Bush, the nonprofit organization developed and administers the Gold Standard, an employee wellness accreditation program that addresses cancer in the workplace. EMD Serono is one of nearly 200 private, nonprofit and government employers in a wide range of occupational categories that have earned Gold Standard accreditation, including the National Cancer Institute (NCI) and a number of NCI-designated cancer centers.

"Nearly all of us are impacted by cancer in some way. At EMD Serono we are committed to making a difference in the lives of patients, their loved ones and healthcare professionals, by accelerating innovation in oncology in order to develop therapies with the potential to transform the way cancer is treated," said Gary Zieziula, President and Managing Director, North America. "This commitment extends to our corporate family through employee wellness programs that are designed to help reduce the risk of cancer, promote early detection and provide quality care."

In order to earn and maintain CEO Cancer Gold Standard accreditation, EMD Serono met specific requirements in corporate culture and health benefits, including: establishing policies and programs to reduce cancer risk by prohibiting tobacco use in the workplace and supporting tobacco cessation efforts; promoting physical activity, healthy nutrition and weight management; providing health insurance options that include detecting cancer at its earliest stages, access to quality care, and participation in clinical trials; promoting employee awareness of these initiatives; and supporting the needs of cancer survivors in the workplace.

Keywords for this news article include: Pharmaceutical Companies, Oncology, Wellness, EMD Serono, Cancer Risk, Risk and Prevention.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
06:25p MERCK : EMD Serono Receives CEO Cancer Gold Standard Re-Accreditation
08/19 MERCK : EMD Serono Receives CEO Cancer Gold Standard ReAccreditation
08/18 MERCK : Presolicitation Notice - Notice of Intent to Sole Source - EMD Millipore..
08/16 MERCK : Millipore teams with TEAM Jaffrey
08/15 DGAP-PVR : Merck KGaA: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der ..
08/15 DGAP-PVR : Merck KGaA: Release according to Article 26, Section 1 of the WpHG w..
08/14 MERCK : SAFC y Stars participaron en el 2016 Team Up Day of Service
08/07 MERCK : Check out some of the numbers behind Greg Cochrane's career
08/04DJMERCK KGAA : Lifts Profit Outlook as Sales Jump -- Update
08/04DJMERCK KGAA : Lifts Profit Outlook as Sales Jump
More news
Sector news : Specialty & Advanced Pharmaceuticals
05:46p FTSE retreats as pharma stocks fall
03:56pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:12pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:11pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
02:15pDJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
08/19 ALPHA FROM EQUAL-WEIGHTING : A Look At Materials
08/10 Bristol's Opdivo Fall-Out Brings Others Into Play
08/05 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q2 2016 Results - Earnings Call T..
08/04 Merck KGaA reports Q2 results
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
Financials (€)
Sales 2016 15 085 M
EBIT 2016 3 275 M
Net income 2016 1 620 M
Debt 2016 10 926 M
Yield 2016 1,27%
P/E ratio 2016 24,22
P/E ratio 2017 22,32
EV / Sales 2016 1,55x
EV / Sales 2017 1,39x
Capitalization 12 529 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 104 €
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Laszlo Radvanyi Senior Vice President & Head-Research
Crocifissa Attardo Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA8.23%14 125
ABBVIE INC9.82%105 953
BIOGEN INC0.97%67 781
KYOWA HAKKO KIRIN CO L..-22.41%8 641
More Results